The Business Research Company’s Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Report 2026 – Market Size, Trends, And Forecast 2026-2035
LONDON, GREATER LONDON, UNITED KINGDOM, August 19, 2026 /EINPresswire.com/ — “The next-generation sequencing (NGS)-based molecular diagnostics market has been rapidly evolving, driven by technological progress and growing demand for precise genetic testing. This sector plays a pivotal role in transforming how diseases are diagnosed and treated by leveraging advanced sequencing techniques to provide detailed molecular insights. Let’s explore the current market size, key growth drivers, regional outlook, and emerging trends shaping the future of this industry.
Current Market Size and Projected Growth of the Next-Generation Sequencing-Based Molecular Diagnostics Market
The market for NGS-based molecular diagnostics has experienced significant expansion over recent years. It is projected to grow from $2.26 billion in 2025 to $2.43 billion in 2026, marking a compound annual growth rate (CAGR) of 7.6%. The strong rise during this historic period is largely due to increased genetic disorder testing, the advancement of high-throughput sequencing technologies, heightened awareness of molecular diagnostics, widespread adoption in clinical laboratories, and constant improvements in sequencing reagents.
Download a free sample of the next-generation sequencing (ngs)-based molecular diagnostics market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28281&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Aug_PR
Looking ahead, the market is anticipated to maintain its momentum, reaching $3.23 billion by 2030 with a CAGR of 7.3%. This forecasted growth is supported by trends such as the incorporation of artificial intelligence (AI) and machine learning into diagnostic processes, the expansion of cloud-based genomic platforms, the creation of portable and point-of-care sequencing devices, the surge in personalized medicine applications, and intensified collaboration between diagnostic and biotechnology companies. Key innovations expected during this period include AI-powered molecular diagnostics, cloud genomic analysis, portable sequencing tools, integrated bioinformatics pipelines, and rapid detection of disease markers.
Understanding Next-Generation Sequencing-Based Molecular Diagnostics Technology
Next-generation sequencing-based molecular diagnostics is a cutting-edge technology that employs high-throughput sequencing to analyze genetic material with exceptional accuracy and speed. This method enables the identification of genetic variations, mutations, and molecular disease markers, offering profound insights into the genetic foundations of health conditions. By combining sequencing technology with advanced bioinformatics, it supports precise, data-driven diagnostic approaches that improve clinical decision-making and patient outcomes.
View the full next-generation sequencing (ngs)-based molecular diagnostics market report:
https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-ngs-based-molecular-diagnostics-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Aug_PR
Rising Infectious Disease Incidence as a Driver of Market Growth
One of the primary factors propelling the expansion of the NGS-based molecular diagnostics market is the increasing prevalence of infectious diseases. These illnesses, caused by pathogens such as bacteria, viruses, fungi, and parasites, disrupt normal bodily functions and have been spreading rapidly due to increased global travel and migration. NGS-based molecular diagnostics offers comprehensive and accurate pathogen detection, speeding up diagnosis by simultaneously identifying multiple infectious agents and enhancing treatment precision. For example, in February 2024, the UK Health Security Agency reported a 10.7% rise in tuberculosis cases in England, with 4,850 infections recorded in 2023 compared to 4,380 in 2022. Such trends underline how the growing burden of infectious diseases is driving demand for advanced molecular diagnostic tools.
Additional Factors Supporting Market Expansion
Besides infectious diseases, other elements are encouraging the growth of this market. These include ongoing technological innovations, improvements in sequencing accuracy and speed, and rising investments in molecular diagnostic infrastructure. Furthermore, increasing awareness among healthcare providers and patients about the benefits of personalized medicine and early disease detection contributes to wider adoption in clinical settings worldwide.
Regional Market Overview with Focus on Next-Generation Sequencing-Based Molecular Diagnostics
In 2025, North America held the largest share of the NGS-based molecular diagnostics market, benefiting from a strong healthcare infrastructure, high R&D investment, and widespread adoption of advanced technologies. However, the Asia-Pacific region is expected to experience the fastest growth during the forecast period. Growing healthcare spending, expanding molecular diagnostic capabilities, rising prevalence of genetic disorders and infectious diseases, and supportive government initiatives are driving this rapid regional expansion. The market report also covers other key regions including South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa, providing a broad perspective on global market trends and opportunities.
Key enhancements in our 2026 market reports include:
• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info
The Business Research Company – www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company“
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
